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Neuromuscular transmission and its pharmacological blockade 
Part 2: Pharmacology of neuromuscular blocking agents
• Leo H.D.J. Booij
2.1. Introduction
Muscle paralysis can theoretically be achieved by (1) 
blockade of stimulus conduction in the motornerve, 
(2) by inhibition of presynaptic acetylcholine synthe­
sis, mobilization, and release, (3) by blockade of post­
junctional acetylcholine receptors, and (4) by block­
ade of excitation-contraction coupling in the muscle. 
In clinical practice blockade of nerve conduction 
(loco-regional anesthaesia) and postjunctional acetyl­
choline receptors are used. Such blockades must be 
controllable, transient, reversible, and without major 
side-effects.
The effects of neuromuscular blocking agents in 
patients is characterized by a wide variability, both in 
the intensity and the time course of action[1]. Apart 
from anatomical and physiological reasons, such as 
interindividual variability in body size and composi­
tion, muscular maturity (age), gender, and variability 
in plasma cholinesterase activity, many other factors 
are important. These factors include interaction of 
relaxants with concurrent medication and the physi­
cal status of the patient. A variety of diseases such as 
hepatic and renal failure, acid-base imbalance, elec­
trolyte shift, and neuromuscular disturbances cause 
pharmacodynamic or pharmacokinetic change in the 
properties of the relaxant administered. Each individ­
ual relaxant has its own pharmacological properties.
2.2. Pharm acology of individual depolariz­
ing relaxants
The only depolarizing drug currently used is suxame­
thonium (succinylcholine), with a structure similar to 
two coupled acetylcholine molecules (Fig, 2.1).
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Structural formulas of acetylcholine and suxame
thonium.
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Abstract
Clinically, neuromuscular blockade is induced with either 
depolarizing or non-depolarizing relaxants. Suxamethonium 
is the only depolarizing relaxant still in use. It is hydrolysed in 
the plasma by pseudo-cholinesterase (plasma 
cho inesterase). In some patients and in particular diseases 
the plasma cholinesterase activity is low and hence the effect 
of suxamethonium prolonged. Suxamethonium is 
characterized by side-effects such as myalgia, fasdculations 
and increase in intraocular, intracranial and intragastric 
pressure. More serious adverse reactions are masseter muscle 
spasm and potassium release, in patients with some 
neuromuscular diseases and increase in extrajunctional 
acetylcholine receptors. As non-depolarizing muscle 
relaxants benzylisoquinolines and steroidal compounds are 
mainly used. Each relaxant has its own pharmacological 
characteristics. The effect of most relaxants depends on liver 
and renal function because the pharmacokinetic behaviour is 
strongly dependent on these organs. Also, acid-base balance 
disturbances, change in temperature, and neurological 
diseases have an effect on the profile of the relaxants. A 
number of drugs (anaesthetics, antibiotics, antiepileptics, 
etc.) have an effect on neuromuscular transmission, and thus 
interact with the relaxants. Some non-depolarizing relaxants 
cause histamine release and cardiovascular effects.
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2.2.1. Pharmacodynamics of suxamethonium
Because of its rapid onset and short duration of 
action, suxamethonium is mainly used for facilitation 
of endotracheal intubation and for relaxation in 
extremely short surgical procedures. The ED95 of sux­
amethonium is 0.51 mg/kg. Plasma cholinesterase, 
produced in the liver, hydrolyses suxamethonium in 
the plasma. Eighty percent of suxamethonium is nor­
mally hydrolysed before the drug reaches the neuro­
muscular junction. With decreased cholinesterase 
activity the effect of suxamethonium is thus enhanced 
and the duration of action is prolonged [2 3].
2.2.2. Side-effects of suxamethonium
The main side-effects of suxamethonium are potas­
sium release, myalgia, and increase in intragastric, 
intraocular, and intracranial pressure. It can trigger 
malignant hyperthermia and rhambomyolysis. During 
a period of six years there were 700 complications in 
Germany of suxamethonium reported. The first signs 
were in 128 cases spasm of the masseter muscle, in 
24 cases severe bradycardia and in 14 cases tachycar­
dia [4]. In 109 cases rhabdomyolysis occurred, 12 
malignant hyperthermia, and 18 cardiac arrest Nine 
patients died. In 105 cases it occurred in children and 
70% were female.
2.2.2.7. Myalgia
Whether suxamethonium is indeed the cause of post­
operative myalgia remains controversial. In a study 
there was no difference in the incidence of myalgia 
after suxamethonium or after vecuronium [5]. 
However, in another study the incidence was 76% 
after suxamethonium, 23% after atracurium, and 
20.8% when no relaxant was administered [6]. 
Administration of a small amount of non-depolizer 
before suxamethonium decreases the incidence 
markedly [7]. Myalgia is more frequently observed in 
female adults, and in patients that are mobilized soon 
after surgery [8]. It characteristically concerns the 
neck, shoulders and chest. The preventive measures 
suggested, including pre-administration of non-depo­
larizing relaxants, benzodiazepines, dantrolene, lido* 
caine, calcium, aspirin, chlorpromazine etc., have vari­
ous degrees of success [9]. However, the general 
opinion now is that myalgia and fasciculations can 
clinically not sufficiently be prevented by whatever 
pretreatment.
2.2.2.2. Intraocular, intra-abdominal, and intracrani­
al pressure
Increase in intraocular pressure with 84%, lasting a 
significant period of time, was demonstrated after 
suxamethonium administration in children [10]. 
Endotracheal intubation increased the pressure by 
only 5%. Increase in intraocular pressure may be dele­
terious in glaucoma and in patients with open eye 
injury. However, a series of patients with eye injury 
has received suxamethonium without extrusion of 
global contents [11]. In a recent study it was again 
demonstrated that suxamethonium causes significant 
increase in intraocular pressure. It was mainly caused 
by a cycloplegic effect of the drug and not by fascicu­
lations of the extraocular muscles [12].
It is not certain whether the increase in intra­
abdominal pressure observed after suxamethonium 
administration is without consequences for the func­
tion of the oesophageal sphincter mechanism. 
According to some experts this can increase the pos­
sibility of regurgitation to occur, although it was dem­
onstrated that in patients with a patent oesophagus 
sphincter the increase in intragastric pressure does 
not exceed the 'barrier pressure' [13],
Increase in intracranial pressure upon suxametho­
nium administration and intubation has been docu­
mented [14]. Although it has also been demonstrated 
in animals that suxamethonium increases intracranial 
pressure, presumably by an increase in cerebral 
bloodflow, this could not be confirmed in patients 
with neurologic injury [15]. Suxamethonium is theo­
retically suspected to increase intracranial pressure by 
various mechanisms, and should thus presumably not 
be used in patients who already have intracranial 
pressure [16 17].
2.2.2.3. Masseter muscle spasm 
Increase in masseter muscle baseline tone is a rather 
common response to suxamethonium administration, 
not only in children, but also in adults [18]. Such 
spasm is, according to some studies, not necessarily 
followed by the hypermetabolic activity connected to 
malignant hyperthermia [19]. However, it has been 
demonstrated that the halothane-caffein test in mus­
cle biopsies of patients with masseter muscle spasm is 
in 59% of the cases positive, indicating susceptibility 
for malignant hyperthermia. In 7% of the patients 
malignant hyperthermia developed after masseter 
spasm [20]. Potassium release after suxamethonium is 
a special problem. It has been reported in a large 
number of diseases and nervous system disorders, 
including burns, head and spinal cord injury, cerebro­
vascular accidents and neuromuscular diseases [21].
In patients susceptible to malignant hyperthermia 
suxamethonium can induce its onset.
2.2.2.4 Potassium release
Administration of suxamethonium leads to short last­
ing potassium release. In several diseased states such 
potassium release is increased and may lead to car­
diac arrest. Potassium release can be exaggerated by 
acid-base balance disturbances [22 23].
After burn trauma, patients are more sensitive to 
suxamethonium [24]. Suxamethonium administered 
to these patients increases the serum potassium con­
centration to levels that induce cardiac arrest [25 26]. 
This occurs after the first few days and up to months 
afterwards. The more extensive the burn trauma is, 
the more pronounced is the potassium release. It is 
speculated to be caused by an increase in the number 
of acetylcholine receptors and their spread over the 
entire (extrajunctional) muscle membrane [27]. 
Suxamethonium can also lead to potassium release in 
patients with neuromuscular diseases. This is also the 
case in still masked disorders in children. Recently 4 
deaths were reported in children after administration 
of succinylcholine in combination with halothane. All 
had massive rhabdomyolysis, most had hyperkalemia 
and acidosis. In the publication 11 similar cases were 
reported from Germany. There is evidence that all 
deaths were due to hyperkalemia [28]. The report 
prompted the Food and Drug Administration (FDA) 
and the manufacturers in North America to change 
the package insert, and recommend not to use suxa­
methonium routinely in children except for emergen-
cy intubation. This resulted in considerable discus­
sions [29-31]. The FDA noted in the discussion that 
from 1990 through 1992 14 cases of sudden hyperka- 
lemic cardiac arrest after succinylcholine had 
occurred in the USA, from which 7 were fatal [32]. 
One of the manufacturers mentioned 20 cases from 
1990 through 1993 with a mortality of 55% [33]. 
They also brought attention to the fact that 36 cases 
can be found in the literature, that the children and 
adolescents were apparently healthy, and that subse­
quently myopathies were demonstrated in all, primar­
ily Duchenne's muscular dystrophy. Therefore it is rec­
ommended not to use suxamethonium in elective 
cases [34],
2.2.4, Decreased plasma cholinesterase activity
Plasma cholinesterase activity is not only low in 
patients with inherited atypical cholinesterase, but 
also in patients with liver disease, pregnancy, and dur­
ing cardiopulmonary bypass, and in patients using 
cytotoxic drugs and anticholinesterases [48-52], It has 
been demonstrated that cardiopulmonary bypass 
does decrease plasma cholinesterase activity by 60%, 
independently whether this was run under normo- 
thermic or hypothermic conditions [53]. After 
approximately 6 weeks the activity is back to normal. 
Furthermore, the plasma cholinesterase activity at 
birth until about six months of age is 50% that of
2.2.2.S. Muscarinic effects
Administration of suxamethonium, especially in chil­
dren, can result in bradycardia [35]. It can be prevent­
ed by atropine or glycopyrrolate. In higher dosages 
suxamethonium can cause sympathetic stimulation 
with hypertension and tachycardia [36]. That suxa­
methonium does increase plasma levels of catechola­
mines, predominantly norepinephrine, and is pre­
vented by pretreatment with non-depolarizers, has 
been confirmed recently [37]. The use of suxametho­
nium is furthermore accompanied by many and var­
ied dysrhythmias (nodal rhythm, ventricular ectopic 
beats) from stimulations of all cholinergic (nicotinic 
and muscarinic) receptors [38], but is also likely 
increased by release of catecholamines when halo- 
thane anaesthesia is administered [39].
2.2.2.6. Phase li blockade
Another problem with suxamethonium is that its 
depolarizing mechanism may, upon long and repeat­
ed administration, or after high doses, change into a 
block with non-depolarizing characteristics. This is 
called phase II block. This is probably due to interfer­
ence with presynaptic acetylcholine receptors [40].
2.2.3. Effect of suxamethonium in patients with 
diseases
The effect of suxamethonium is principally not altered 
in patients with isolated renal disease. However, in 
these patients suxamethonium can lead to a more 
pronounced potassium release, leading to dangerous 
serum potassium concentrations. Suxamethonium is 
metabolized by plasma cholinesterase, which is pro­
duced in the liver. In such patients the effect of suxa­
methonium can thus be enhanced. It is generally 
accepted that on the one hand respiratory and meta­
bolic acidosis antagonize the effect of suxametho­
nium. Respiratory and metabolic alkalosis on the 
other hand potentiate the effect of suxamethonium. 
In patients with central motor neuron lesions hyper- 
kalaemia is induced by suxamethonium; in patients 
with lower motor neuron lesions hypersensitivity 
exists [41]. Muscular contractures may occur sponta­
neously or following suxamethonium administration 
in denervated muscles. In amyotrophic lateral sclero­
sis suxamethonium may induce a myotonia-like con­
tracture [42]. Myasthenic patients are resistant to suxa­
methonium, and phase II block may develop early 
[43-46]. However, if the patients are on anticholines­
terase treatment increased sensitivity may be 
observed [47].
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Table 2.1 Pharmacodynomic profile o f non-depolarizing relaxants as rounded figures
Relaxant ed90
(mg/kg)
Onset
(min)
Alcuronium 0.25 6.0
Atracurium 0.25 6.5
Cisatracurium 0.05 7.5
Doxacurium 0.03 7.5
Gallamine 2.50 6.0
Metocurine 0.30 7.0
Mivacurium 0,10 4.0
Pancuronium 0.05 5.0
Pipecuronium 0.05 6.5
Rocuronium 0,40 4.0
Tubocurarine 0.45 10.0
Vecuronium 0.05 4.5
adults. Between three and six years it is 30% higher 
than in adults [54]. In the elderly (> 70 years) the 
plasma cholinesterase activity is approximately 25% 
lower than in younger adults [55].
Plasma cholinesterase activity is inhibited by the 
anticholinesterases neostigmine and pyridostigmine, 
but not by edrophonium. When suxamethonium is 
administered after reversal of a non-depolarizing 
block with anticholinesterases, its effect is thus 
enhanced and prolonged [56],
2.3 .Pharm acology of individual non-depo­
larizing neurom uscular b locking agents
The currently clinically used non-depolarizing neuro­
muscular blocking agents either have a benzylisoqui- 
noline or aminosteroidal structure. A variety of factors 
determine the pharmacodynamic profile (onset, 
duration, and recovery) of relaxants in individual 
patients. Amongst them are the type and depth of 
the anaesthetic administered, interactions with con­
currently administered drugs and the age and physi­
cal status of the patient Some of the alterations in the 
pharmacodynamics can be explained by changes in 
the pharmacokinetic behaviour of the drug in that 
particular patient. Various authors have demonstrated 
a direct relationship between the plasma concentra­
tion of the relaxants and the degree of neuromuscular 
blockade [57 58].
2.3.1. Benzylisoquinollnes
The development of clinically useful muscle relaxants 
started with the examination of the arrow poison pro­
duced from Chondodendron and Strychnos plant 
species. This poison was used by some Indian tribes in 
the northern part of South America. From this poison, 
alkaloids (respectively chondocurine and toxiferine I) 
were extracted that served as the basis for the devel­
opment of the benzylisoquinoline-type relaxants [59].
2.3.7.7. Tubocurarine
Tubocurarine, a monoquarternary compound, is the 
oldest representative of the benzylisoquinoline type 
muscle relaxants (Fig. 2.2). It is excreted unchanged 
in the urine, with the liver a secondary pathway.
A portion of the injected drug is stored in body tissues
Durzs &ur9o Rec R-
(min) (min) (min)
30 65 30
20 35 10
20 40 10
85 120 40
50 90 45
60 95 35
15 25 5
35 75 35
60 80 30
15 30 10
35 95 60
10 25 10
for a longer period, then slowly mobilized and excret­
ed [60]. The onset of tubocurarine is slow, its duration 
is long, and its recovery is slow (see Table 2,1). The 
usual intubating dose is 0.5-0.6 mg/kg; maintenance 
doses are 0.1-0.2 mg/kg. The pharmacokinetic beha­
viour of tubocurarine has been studied extensively 
(see Table 2.2). In burn patients, and in patients with 
hepatic or renal failure, the duration of action of tubo­
curarine is prolonged. With tubocurarine, marked 
histamine release and ganglion blockade lead to 
hypotension and reflex tachycardia. Flushing and 
bronchoconstriction can be observed. Following sux­
amethonium, a tubocurarine block is prolonged.
2.3.7.2. Metocurine
Metocurine is a methylated derivative of tubocurarine 
(see Fig, 2.2). The ED95 is 0.30 mg/kg, and the main­
tenance dose 0.05-0.1 mg/kg. Its pharmacokinetic 
behaviour is similar to tubocurarine, although there is 
more dependence on renal excretion. It has fewer 
cardiovascular si de-effects and causes less histamine 
release than tubocurarine. In the clinic, both com­
pounds are nowadays replaced almost completely by 
other non-depolarizing relaxants. Metocurine is not 
available in Europe.
2.3.7.3. Atracurium
Atracurium exists of a racemic mixture of 10 stereo­
isomers, most of which are pharmacologically active 
(see Fig. 2.2) [61]. All isomers, however, have a phar­
macodynamic profile and a pharmacokinetic behavi­
our which is different from each other [62 63]. After 
administration of the ED90 dose of atracurium (0.19 
mg/kg), the onset of action is 6.7 min, the clinical 
duration 17.1 min, and the total duration 32.0 min 
(see Table 2.1). The recovery rate is 12.0 min [64]. 
After an initial (intubating) dose of atracurium, 0.4- 
0.5 mg/kg, either intermittent bolus (0.1-0.15 mg/kg 
every 20-30 min) or continuous infusion (0.3-0.6 
mg/kg/h) can be used to maintain the neuromuscular 
blockade. Even in ICU patients there is easy control of 
the blockade [65]. Compared to other non-depolariz­
ing relaxants, atracurium has a short elimination half- 
life (see Table 2.2).
One of the main disadvantages of atracurium is the 
histamine release at higher clinical doses in about 
30% of patients. The signs are skin flush, hypoten-
sion, tachycardia, and bronchoconstriction. Slow 
administration and avoiding high dosages largerly 
overcomes the problem of histamine release. 
However, recently it was found that administration of 
atracurium in patients treated with cimetidine result­
ed in a profound decrease in arterial blood pressure 
[66]. In this study combined H1 and H2 receptor 
blockade did result in attenuation of histamine 
release.
It was initially thought that the metabolism of atra­
curium was by temperature and pH dependent 
Hoffmann degradation into laudanosine, an acrylate, 
and a monoquarternary ester, which was further 
degraded to a second laudanosine molecule and an 
acrylate ester (see Fig. 2.3) [67 68]. However, the 
plasma concentration of laudanosine, both in young­
er and elderly patients, is highest immediately after 
injection of atracurium [69].
This is incompatible with spontaneous (Hoffmann) 
degradation of atracurium, therefore, another rapid 
but limited metabolism, proportional to the dose of 
atracurium administered, must also be present [70], A 
large fraction of injected atracurium is degraded rap­
idly, a small part causes the neuromuscular block and 
leads to a long-lasting slow production of laudano­
sine. It has also been suggested that non-specific ester 
hydrolysis plays an important role in the metabolism 
of atracurium. Neither true cholinesterase, nor plasma 
cholinesterase, has any effect on the metabolism or 
effects of atracurium. The metabolite laudanosine 
may cumulate especially if high doses are adminis­
tered. Laudanosine can cause excitatory effects on the 
central nervous systems in such situations. Atracurium 
has a slower onset and prolonged effect during hypo­
thermic cardiopulmonary bypass [71 ].
2.3.1.4. Cisatracurium (BW 51W89)
Recently, studies have started on BW 51W89, one of 
the 10 stereoisomers of atracurium, with a greater 
potency (ED95 = 50 /ug/kg) than atracurium, and a 
similar time course of neuromuscular blocking activity 
[72]. This 1R c/s-1'c/s isomer constitutes 15% of the 
commercial atracurium mixture. Its onset of action is 
slower than that of atracurium [73], and is paralleled 
with less favourable intubating conditions, making 
higher ED95 multiples necessary for intubation [74]. 
The compound causes an increase in plasma hista­
mine concentration in some patients, but does not 
lead to clinical signs of histamine release or related 
cardiovascular effects [75], The results were con­
firmed in a study in patients with an impaired cardio­
vascular system [76]. BW 51W89 is metabolized by 
Hoffmann degradation and ester hydrolysis. Its phar­
macokinetics are similar to that of atracurium.
In patients with chronic renal failure, it was demon­
strated that 51W89, contrary to atracurium, had a 
significantly lower mean plasma clearance than in 
patients without renal failure [77]. This coincides with 
a tendency to a slower recovery [78]. In the first study 
it was also demonstrated that 51W89 results in less 
laudanosine to be formed, both in patients with and 
without renal failure. This may indicate that 
Hoffmann elimination is less important with 51W89. 
Neuromuscular blockade can be maintained by con­
tinuous infusion of cisatracurium.
2.3.1.5. Mivacurium
Mivacurium is a short-acting bisquarternary relaxant 
that resembles atracurium in its structure, has a slow 
onset, but a short duration of action (see Fig, 2.2). 
The ED95 (0.07-0.08 mg/kg) dose of mivacurium has, 
during balanced anaesthesia, an onset of 3-5 min, a 
clinical duration of 15 min, a total duration of 25-30 
min, and a recovery rate of 5-7 min (see Table 1.1) 
[79], The short duration of action of mivacurium can 
be explained by a rapid plasma clearance (see Table 
2.2). The intubating dose is 0.15-0.2 mg/kg. 
Mivacurium consists of three stereoisomers (trans- 
trans, cis-trans, cis-cis), one of which (c/s-c/s) is inac­
tive, but contributes largely to the long elimination 
half-life of the mixture [80].
Pharmacokinetically, the isomers behave differently 
from each other [81]. The volumes of distribution of 
mivacurium are comparable with those for other non­
depolarizers, but the clearance is significantly faster. 
In clinical dosages mivacurium has no cardiovascular 
effects [82], There is histamine release at high doses, 
thus some decrease in arterial pressure and increase in 
heart rate can then occur [83-85]. Pretreatment with 
mivacurium before suxamethonium administration 
leads to a marked antagonistic effect on the develop­
ment of the suxamethonium-induced block. How­
ever, administration of suxamethonium does not 
influence the effect of mivacurium administered 
thereafter [86]. In children mivacurium is less potent 
[87].
Mivacurium is metabolized by plasma cholinester­
ase at a rate 60-80% that of suxamethonium, into a 
pharmacologically inactive quarternary mono-ester, a 
quaternary amino alcohol, and dicarboxylic acid (see
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Fig. 2,4) [88 89]. The metabolites are excreted in bile 
and urine. Also a small amount of unchanged mivacu- 
rium is excreted in this way. Duration of action thus 
varies with plasma choiinesterase activity, and a num­
ber of such cases showing prolonged mivacurium 
effects have been published [90-95].
Although during and after cardiopulmonary bypass 
a 60% decrease in choiinesterase activity is observed, 
the effect of mivacurium during and after this proce­
dure in normothermic conditions is not prolonged 
[96]. A case has been reported where a young patient 
with dermatomyositis and low plasma choiinesterase 
activity had prolonged paralysis after mivacurium, 
while the blockade could not be reversed with edro­
phonium [97], Since edrophonium, unlike neostig­
mine, does not inhibit plasma choiinesterase, it was 
expected that edrophonium would be more suitable 
for reversal of mivacuriurn-induced block* However, in 
a prospective study, it was demonstrated that edro­
phonium is not effective in the reversal of mivacurium 
[98]. In contrast, another author found edrophonium 
to be a reliable reversing agent during intense miva- 
curium-induced blockade [99]. A patient with end- 
stage renal failure, and presumably a low cchoiinester- 
ase activity, had a prolonged effect after mivacurium, 
while the blockade could not be reversed with neo­
stigmine [100]. This is most likely due to the fact that 
the reversal agent inhibits cholinesterases, and thus 
slows down the metabolism of mivacurium. Two 
recent case reports describe the successful use of puri­
fied human choiinesterase to antagonize profound 
mivacurium-induced neuromuscular blockade [101]. 
Although mivacurium is reversible with anticholines­
terases, some problems in reversal with neostigmine 
have been described in patients with atypical cho­
iinesterase [102 103].
Compared to adults, children need more mivacuri­
um to reach the same degree of blockade; however, 
the blockade recovers more quickly [104].
The compound is suitable for continuous infusion 
[105]. Increase in single dose causes a disproportion- 
ally small increase in the duration of action, and has 
no effect on the recovery rate; however, cardiovascu­
lar effects may appear. After rapid, but not on slow 
injection of larger bolus doses (2-3 times ED95), a 
transient decrease in arterial pressure may occur. This 
is accompanied by facial flushing and an increase in
serum histamine concentration. It occurs in 30% of 
the cases when 0.2 mg/kg mivacurium is adminis­
tered. Inhalational anaesthetics do reduce the ED95 by 
20-30% [106].
2.3.7.6. Doxacurium (BWA938U)
Doxacurium is a long-acting bisquarternary com­
pound (see Fig. 2.2). The solution contains 0.9 vol.% 
benzylalcohol as a preservative. It is the most potent 
relaxant presently available (ED95 30 jug/kg); how­
ever, its onset is slow (10-13 min), its duration of 
action is long (clinical 57-80 min, total 74-128 min), 
and its recovery rate is slow (32-50 min) (see Table
2.1) [107-109]. Good intubation conditions exist 5 
min after administration of twice the ED95 [110]. The 
pharmacodynamic profile is highly variable, and is 
related to age, obesity and type of anaesthetic [111]. 
Proper maintenance doses are 0.005-0.01 mg/kg. 
The pharmacokinetic behaviour of doxacurium has 
been studied (see Table 2,2), Even at high dosages it 
does not alter the cardiovascular parameters [112 
113]. Doxacurium consists of three stereoisomers, is 
hydrolysed by plasma choiinesterase at a rate 6% that 
of suxamethonium, and 40% is excreted unchanged 
in the urine with small amounts in the bile. Thus is the 
duration of action prolonged in patients with renal 
failure [141]; but hepatic diseases appear to have no 
influence [115]. The speed of its antagonism by neo­
stigmine is also highly variable. Although doxacurium 
is not associated with histamine release, a case in 
which cutaneous flush and hypotension occurred has 
been described [116]. The solution contains 0.9 
vol.% benzylalcohol as a preservative. Inhalational 
anaesthetics decrease the ED95 by 20-40%. 
Compared to balanced anaesthesia, enflurane does 
decrease the EDgo by 43%, isoflurane by 31% and 
halothane by 20% [117]. When the same dosages are 
administered, the inhalation agents prolong the dura­
tion of action and delay the recovery rate of doxacu­
rium. In children the onset of action is more rapid, the 
duration is shorter, and there is a need for relatively 
higher doses of doxacurium than in adults [118 119]. 
The blockade is reversable with neostigmine. Some 
studies found poor reversibility with edrophonium 
but adequate with neostigmine [120]. Others found 
adequate reversibility with both agents in the single 
twitch stimulation but found a T4 : T1 ratio less than
0.6 even 20 min after administration of the reversal 
agents. Doxacurium has recently been introduced in 
the clinic.
Ac
2.3,1.7. New developments with benzylisoquinolines 
Some benzylisoquinolines were tested for short dura­
tion of action in the past. In the development of ultra- 
short relaxants, studies were performed with BW785U 
(onset 60-90 s, duration 10-12 min, recovery rate 25- 
75% 2.5-3 min); however, marked hypotension due 
to histamine release prevented further clinical studies.
Both BW 252C64 and BW 403C65 were short and 
free from cardiovascular effects in animal experi­
ments. However, important cardiovascular effects 
were demonstrated in preliminary human studies 
with BW 403C65, while hypersalivation and bronchial 
secretion were observed with BW 252C64. Further­
more, BW 252C64 could not be reversed with anti­
cholinesterases [121]; this might indicate a basically 
depolarizing or other unspecific mechanism of action.
BW954U has been tested in animals recently, and 
showed to be a potent short-lasting blocker with min­
imal cumulative effect and a reasonable cardiovascu­
lar safety [122]. It has significant prejunctional effects.
2.3.2. Aminosteroids
In Africa, poisons were extracted from Malouetia 
bequaertiana, which were found to cause paralysis. 
From these poisons, Malouétine was extracted, and 
this served as the basis for the steroidal relaxants
[123]. The basic structure of the steroidal non-depo- 
larizing muscle relaxants contains an androstan skele­
ton, with 1,2-amino alcohol functions stereoselective- 
ly introduced into the steroidal nucleus. This results in 
two acetylcholine-like moieties, which are important 
for the interaction with the acetylcholine receptors
[124]. In steroidal relaxants, acetylcholine-like moie­
ties are present both in the A and D rings. The acetyl­
choline-like moiety at the D ring is apparently respon­
sible for binding the molecule to the nicotinic acetyl­
choline receptor at the neuromuscular junction sites, 
and the acetylcholine-like moiety at the A ring for 
binding to muscarinic receptors at other sites [125 
126]. For high potency, it is probably essential to have 
two nitrogen atoms in the molecule, with at least one 
of them quarternized. Bowman et al. demonstrated a 
relationship between potency and onset in anaesthe­
tized cats, based on this structure-activity relation­
ship. Compounds with a low potency were demon­
strated to have a faster onset of action than relaxants 
with a higher potency. Combinations of steroidal 
relaxants interact in an additive manner [127].
2.3.2.1. Pancuronium
Pancuronium is one of the most frequently used non­
depolarizing muscle relaxants, both in anaesthesia 
and in intensive care (see Fig. 2.5). After administra­
tion of the ED90 (0.06 mg/kg) the onset is 4.9 min, 
the clinical duration 34.4 min, the total duration 73.2 
min, and the recovery rate 31.9 min (see Table 2.1)
[128]. The intubating dose is 0.8-0.1 mg/kg. For 
repeated administration, doses of 0.01-0.05 mg/kg 
every hour are used. Although pancuronium is long 
lasting, and therefore theoretically not an appropriate
drug for continuous infusion, it has been used in this 
way.
Pancuronium is metabolized mainly by deacetyla-
Pancuroniu
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Figure 2.5
Structural formulas of the aminosteroidal non-depolariz 
ing relaxants pancuronium, vecuronium , pipecuronium ,
and rocuronium.
tion in the liver, and thereafter excerted in the urine 
(see Fig. 2.6), The metabolites (3-OH, 1 7-OH, and 
3,7-di-OH) are considerably less potent as relaxants
[129]. Since their concentrations are also low, and 
their pharmacokinetics are comparable to pancuro­
nium, they contribute little to the neuromuscular 
blocking effect.
About 40-60% of pancuronium is excreted in the 
urine and 11% in the bile. Pancuronium increases 
heart rate, arterial pressure, and cardiac output. This 
is a sympathomimetic and anticholinergic effect It 
can lead to increased myocardial oxygen consump­
tion and a decrease in myocardial oxygen supply. The 
sympathomimetic effect may also alter pulmonary cir­
culation and result in pulmonary vasoconstriction, 
and thus in ventilation/perfusion mismatch. This has 
especially been noted in neonates [1 30].
Pancuronium causes no histamine release. 
Pancuronium inhibits plasma cholinesterase and thus
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[131 132]. The 3-OH-metabolite has neuromuscular 
blocking effects, but is only produced In small 
amounts (1 2 %  of the maternal compound adminis­
tered). When, however, vecuronium is administered 
for a long period of time, or in large doses, this 
metabolite may contribute to the blockade [133]. 
This is seen as cumulation, e.g. increase in recovery 
time. The 3-OH metabolite has 80% the neuromuscu­
lar blocking potency of vecuronium. It is excreted for 
2 0 %  by the kidneys and the remainder via the liver 
r2 [134]. Approximately 30% of vecuronium is excreted 
unchanged in the urine. The duration of the vecuroni­
um-induced neuromuscular block is dependent on 
hepatic function and less on renal function. Its effect 
can thus be prolonged in patients with hepatic fail- 
F igu re  2-6 ure, and also, to some extent, in patients with renal 
The metabolism of pancuronium, dysfunction. This can be explained pharmacokineti-
cally.
prolongs the effect of suxamethonium and possibly 
mivacurium.
2.3.2.2. Vecuronium
Vecuronium (see Fig. 2.5) is a monoquarternary non­
depolarizing neuromuscular blocking agent, that, 
when administered at an ED95 dose (50 ¿vg/kg), 
results in an onset of 4.5 min, a clinical duration of 
11.6 min, a total duration of 24.9 min, and a recovery 
rate of 9.7 min (see Table 2.1). After an initial (intu­
bating) dose of usually 0.08-0.15 mg/kg, the block­
ade can be maintained by intermittent doses (0 .0 1 -
0.04 mg/kg every 20-30 min) or continuous infusion 
(0.075-0.10 mg/kg/h). The pharmacokinetic data on 
vecuronium are given in Table 2 .2 . Even at high 
doses, vecuronium does not release histamine, and 
has no effects on the cardiovascular system. The fre­
quently observed bradycardia at induction of anaes­
thesia is the result of the bradycardic effect of other 
drugs, e.g. opioids and intravenous anaesthetics.
Hepatic uptake lowers the blood concentration of 
vecuronium, which subsequently is metabolized in 
the liver by deacetylation into three possible meta­
bolites: 3-OH, 17-OH, and 3,17-di-OH vecuronium
2.3.2.3. Pipecuronium
Pipecuronium (see Fig. 2.5) is a bisquarternary relax­
ant (ED95 45 jug/kg) with a slow onset and a long 
duration of action, similar to pancuronium (see Table
2.1) [135 136, 22, 77]. Increasing the dose shortens 
the onset, but prolongs the duration. There is wide 
interindividual variability in the response to pipecuro­
nium. Intubation with twice the ED95 dose is possible 
after 2 min. The pharmacokinetic profile of pipecuro­
nium is slightly different from that of pancuronium, 
with a greater plasma clearance and a larger VDSS (see 
Table 2.2) [138]. The pharmacokinetic parameters of 
pipecuronium are significantly changed in patients 
undergoing renal transplant as compared to normal 
patients. The dose requirement for pipecuronium is 
not different between children and adults [139]. 
Once some spontaneous recovery of neuromuscular 
block is visible, the blockade can be adequately 
reversed with neostigmine. Edrophonium, however, is 
an unreliable antagonist for pipecuronium [140]. 
Pipecuronium has no histamine release or relevant 
cardiovascular effects [141 -144].
Approximately 40% of the dose administered is 
excreted via the kidneys and thus the effect is pro­
longed in renal failure [145]. The remainder of the
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Tab le  2-2 Pharmacokinetic data in 'normal patients' for clinically used non-depolarizing muscle relaxants
as rounded figures
Reiaxant VDc
0/kg)
(VDss)
d/kg)
C/p
(ml/kg/ml) 
n
fl/2ß
(min)
Protein
binding
(96)
Alcuronium 0.15 0.35 1.34 143 75
Atracurium 0.05 0 , 2 0 6 . 6 21 80
Cisatracurium 0.06 0.15 5.3 30 wé
Doxacurium 0 .0 1 0 . 2 2 2.76 99 30-35
Gallamine 0 . 1 0 0 . 2 0 1 .2 134 15
Metocurine 0.05 0.57 1 .2 360 30-45
Mivacurium 0 .1 1 70 18
Pancuronium 0 . 1 0 0.26
>
1 .8 132 85
Pipecuronium 0 .1 1 0.31 2.3 137 —
Rocuronium 0.04 0 .2 1 3.7 97 -
Tubocurarine 0.03 0.25 2.4 84 35-55
Vecuronium 0.07 0,27 5.2 71 70
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drug is slowly deacetylated in the liver and then 
excreted in the bile.
2.3.2.4. Rocuronium (ORG 9426)
Rocuronium (see Fig. 2.5) is a new intermediately- 
long acting monoquarternary relaxant with a phar­
macodynamic profile comparable to that of vecuroni­
um (see Table 2.1). Rocuronium, however, is stable in 
solution. The ED90 of 0.3-0.4 mg/kg results in an 
onset of 1.5-4 min, a clinical duration of 18.8 min, a 
total duration of 32.1 min, and a recovery time of 8 -
12 min [27]. When an intubating dose of 0.5 mg/kg 
rocuronium (twice the EC90) is used, the intubating 
conditions at 1 min were comparable to those after 
suxamethonium in 95% of the patients [146-150].
Rocuronium is generally free from cardiovascular 
effects or histamine release [151 152]. However, high­
er doses of rocuronium can cause a slight increase in 
heart rate and a significant rise in blood pressure, pre­
sumably through a vagolytic mechanism [153].
Rocuronium can be used in continuous infusion to 
maintain neuromuscular blockade. Inhalational 
anaesthetics potentiate the effects of rocuronium 
[154-156].
Rocuronium can be reversed by both edrophonium 
and neostigmine; however, neostigmine is more effi­
cient [157].
The pharmacokinetic behaviour of rocuronium is 
similar to that of vecuronium, but with smaller vol­
umes of distribution (see Table 2.2) [158]. Although 
rocuronium is taken up in the liver, and mainly excret­
ed in the bile, the kidneys seem to play an important 
role in the pharmacokinetics of rocuronium since in 
normal patients 33% of rocuronium was found 
excreted unchanged in the urine [159 160]. Despite 
this, renal failure does not appear to influence the 
pharmacodynamics of rocuronium.
The main advantage of rocuronium over other 
relaxants is its fast onset of action and the ability to 
intubate the patient within 1.5 min after its adminis­
tration [161 162],
2.3.2.5. New developments with steroidal relaxants
A large number of steroidal relaxants have been test­
ed in animals and some in humans [163]. Some com­
pounds with an ultrashort duration o^f action have 
been investigated in animals and humans. Org 6368, 
Org 7617, Org 8764, Org 9273, Org 9453, Org 
9487, Org 9489, Org 9991, and Org 9616 were stud­
ied [164-168].
In humans, Org 7617 showed a moderate fall in 
arterial pressure, an increase in heart rate, and can 
probably cause histamine release [169]. Initial clinical 
studies were also performed with Org 9453 and Org 
9489 [170], Org 9489 appeared to have an interme­
diate long duration of action, Org 9453 a short one. 
Org 9273 had a time course of action similar to that 
of vecuronium, but at higher dose ranges cardiovas­
cular effects were observed due to vagolysis [171 ].
A higher lipophilicity of steroids was demonstrated 
to relate with faster equilibration of drug concentration 
between plasma and effect compartment, and with a 
higher plasma clearance of unbound drug. A higher 
lipophilicity was also related with loss in receptor affin­
ity (lower potency), shorter onset time and duration of 
action [172]. Lower potency indeed correlated with a 
faster onset of action as found in animals [173].
ANQ 9040 is another steroid with a rapid onset of 
action. In human volunteers it, however, exerted 
tachycardia and hypotension as a result of histamine 
release.
Org 9487 is probably the most promising, and 
undergoes more extensive clinical testing. It is charac­
terized by a rapid onset similar to that of suxametho­
nium, and an intermediate duration. Its main advan­
tage is its easy reversibility, even at deep degrees of 
neuromuscular blockade [1 74 175].
The pharmacodynamic data of some compounds 
in humans are given in Table 2.3.
Chandonium (HS-310) is a steroidal relaxant devel­
oped in India. Pharmacological studies with these 
aza-steroidal compounds were performed in 
Glasgow. In cats, chandonium had a rapid onset and 
short duration of action, but was accompanied by 
cardiovascular effects due to vagolysis and cardiac 
noradrenaline reuptake block, which resulted in tach­
ycardia [176]. Preliminary studies in humans lead to 
the same conclusions (Booij, Agoston 1976, unpub­
lished results) which prevented further development. 
However, human studies with the compound were 
again performed in India [177], HS-342 is an ana­
logue that in animals causes a fast onset and short- 
lasting neuromuscular blockade. However, it also pos­
sess a strong vagolytic and autonomic ganglion 
blocking effect [178]. The compound has not been 
tested in humans. It is very doubtful whether either of 
these two compounds will ever reach the western 
market.
RGH 4201 (Duador) is the 3a isomer of chando­
nium. It was, like pipecuronium, developed in 
Hungary. Its pharmacodynamic profile is similar to 
that of vecuronium; in humans the ED90 is 0.4 
mg/kg, which has an onset time to maximal effect of
6.4 min, a duration to 25% recovery of 28.4 min and 
a recovery index of 51.9 min [1 79]. The compound 
seems to be used in East European countries.
Tab le 2.3 Pharmacodynamic data on some
investigational steroidal refaxants in 
humans
ED90 
(mg./kg)
Onset
(min)
Duration25
(min)
Org 761 7 3.5 1 .1 1 2 . 0
Org 9273 0.3
Org 9453 1.5 1 . 2 8.5
Org 9487 1 . 2 1.5 9.0
Org 9489 0.5 1 . 6 2 2 . 0
2.3.3. Older muscle relaxants
2.3.3.1. Alcuronium
Alcuronium, a synthetic derivative of the natural 
product toxiferine, is a bisquarternary compound, 
that is not metabolised, but excreted for 80-85% 
unchanged in the urine, with the rest in the bile (see 
Fig. 2.7). The pharmacodynamics of alcuronium are 
similar to those of pancuronium, pipecuronium and 
doxacurium with a slow onset and a long duration of 
action (see Table 2.1). The intubating dose of alcuro­
nium is 0.2-0.25 mg/kg. Its pharmacokinetics have
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Structural formulas for the older non-depoiarizing relax
ants alcuronium and gallamine.
expected [188 189]. Because most of the compounds 
have anticholinesterase effects themselves, the ability 
to reverse such compounds with anticholinesterases 
can be impaired. Most of them showed histamine 
release [103] with cardiovascular effects, and some 
had tachyphylaxis [190 191], another reason why 
they were not further developed.
Other developments are the bis-thiazolium di­
esters [192]. Most of these compounds so far caused 
vagolytic effects. Some are reversible by neostigmine, 
others are not. In the group both intermediately long- 
acting (atracurium-like) and short-acting (suxametho 
nium-like) substances are present when they were
tested in the cat.
In Russia a number of bulky ester compounds have 
been developed and seem to be in clinical use: ana- 
truxonium, cyclobutonium, truxilonium and diado- 
nium [41]. Diadonium was tested in animals in the 
USA. The resulting neuromuscular blockade was rapid 
in onset and had a short duration, but was accompa­
nied by moderate hypotension and mydriasis. In 
guinea pigs and monkeys the blockade was reversible 
by neostigmine; however, in mice, rat and also in 
humans this was not the case [193].
G1-64 is a tropanyl ester derivative with neuromus­
cular blocking activity. In animals it does have a short 
onset (shorter than atracurium or vecuronium) and 
relatively short duration of action (comparable to vec­
uronium and atracurium). In the act it is slightly more 
vagolytic than pancuronium. To my knowledge 
human studies have not yet been done with tropanyl 
esters.
been studied (see Table 2.2) [180]. It causes some 
vagolysis and has minimal effect on the blood pres­
sure. It does cause mild histamine release.
Continuous infusion for maintenance of 95% 
decrease in contraction force of the adductor pollicis 
muscle has been described with 0 .0 0 1  mg/kg/min.
23.3.2. Gallamine
Gallamine is a completely synthesized trisquarternary 
compound, characterized by a strong vagolytic effect 
(see Fig. 2.7). The intubating dose of gallamine is 2.2-
2.4 mg/kg. Because of the vagolysis and the slight 
sympathomimetic effect, gallamine is nowadays 
almost solely used as a pre-curarizing agent before 
the use of suxamethonium. Gallamine's pharmacoki­
netics is described in a two-compartment model
[181]. It is almost entirely excreted by the kidneys
[182]. Gallamine is contraindicated in patients with 
an iodine allergy, since it is an iodine salt.
2.3.4. Ester type non-depolarizing relaxants
Already in 1973 some short-acting esters were tested 
in animal experiments (D-188, Jj-142 and HH-85) 
[183 184]. However, observed vagolytic cardiovascu­
lar effects prevented their further development. 
Intermediate-acting esters were also tested (BW985U, 
BW785U, BW444U) [185-187]. They all are hydro­
lyzed by plasma cho I in esterase into inactive deriva­
tives. Some of the compounds were preliminary test­
ed in humans where they were longer-acting than
2 .4.Pharm acok inetics of non-depolarizing 
relaxants
The concentration of relaxants at the receptor, i.e. in 
the biophase, is of utmost importance for their clinical 
effect The biophase concentration is in equilibrium 
with the plasma concentration, which in turn is 
dependent on the dose of relaxant administered, and 
on the pharmacokinetic behaviour of that individual 
drug. Hence a relation exists, as with many other 
drugs, between plasma concentration and the degree 
of paralysis. The pharmacokinetic behaviour of mus­
cle relaxants determines to a wide extent the clinical 
effect. The time course of action of NMBDs is thus a 
reflection of the plasma concentration decay curve. 
Concentration decay curves are characterized by a 
number of parameters (slopes, intercepts, etc,) from 
which the pharmacokinetic variables (half life times, 
plasma clearance, volumes of distribution, etc.) can 
be calculated.
When the plasma concentration at which a particu­
lar neuromuscular block exists is known, the single 
bolus dose or the rate of continuous infusion to reach 
that degree of blockade can be calculated [194].
The pharmacokinetic behaviour of drugs is influ­
enced by many disease states. Some patients receiv­
ing an anaesthetic may have one of these diseases 
and thus knowledge of the pharmacokinetic changes 
is important. Changes in renal function have signifi­
cant impact on the clearance and the t1/2(V but in gen­
eral have only a minimal effect on the volume of dis­
tribution and t 1/ia of the relaxants. In obstructive liver 
diseases (cholestasis) clearance of many relaxants is 
decreased, leading to a prolonged elimination half-
life [195]. In cirrhosis there is with most relaxants an 
increased initial volume of distribution, most likely 
caused by an increased extracellular fluid space in 
these patients. This results in resistance towards many 
non-depolarizing relaxants.
With age many physiological functions are altered, 
including hepatic and renal function. Therefore the 
pharmacokinetic behaviour of drugs frequently 
changes with age. In neonates and infants there is fre­
quently a decreased plasma clearance and prolonged 
elimination half-life, with prolonged paralysis. The 
initial volume of distribution is increased, leading to 
resistance to relaxants.
2.5.Effects of concurrent d iseases on the 
effect of m uscle relaxants
Many diseases can interfere with either the pharma­
codynamics or the pharmacokinetics of muscle relax­
ants. They result in an increased or decreased sensitiv­
ity to the relaxant (degree of neuromuscular block­
ade), and a change in the time course of action 
(onset, duration and recovery rate).
There is a variety of reasons why diseases interact 
with the pharmacodynamics of a muscle relaxant. 
Some diseases do interfere with the generation and 
conductance of stimuli in the central or peripheral 
motor nerve system. This will lead to a change in ace­
tylcholine release at the neuromuscular junction. 
Other diseases directly interfere with the neuromus­
cular junction either through interference with the 
amount of acetylcholine synthesized, mobilized, 
released or metabolized, or with the number of post­
junctional acetylcholine receptors (up- and down-reg- 
ulation) available. The resulting change in the margin 
of safety of neuromuscular transmission leads to an 
altered effect of the relaxants. Yet other diseases inter­
fere with the contractility of the muscles themselves, 
and appear to lead to a change in the pharmacody­
namics of the relaxants. All such interactions may not 
only be a direct result of the disease itself, but may 
also be related to the drugs that are administered for 
the treatment of that disease [196],
2.5.1. The effect of renal disease
Most muscle relaxants are water-soluble ionized quar- 
ternary ammonium compounds, and thus depend on 
glomerular filtration, tubular excretion and tubular 
reabsorption for their rate of body clearance (see 
Table 2.4) [197]. The relaxants with a large renal 
excretion are heavily affected by renal disease (i.e. 
gallamine, metocurine, alcuronium, pancuronium). 
Those with an intermediate renal excretion are vari­
ably affected (i.e. vecuronium, rocuronium, tubocura- 
rine), and those with low renal excretion are minimal­
ly affected (i.e. suxamethonium, atracurium, mivacu- 
rium).
Suxamethonium is metabolized in the plasma by 
pseudo-cholinesterase and is, therefore, not affected 
by renal failure. However, it may increase the serum 
potassium level, which may lead to dangerous con­
centrations.
In renal failure the non-depolarizers maintain a 
higher plasma concentration for a longer period of 
time, unless other routes for elimination exist. Also, 
other factors such as altered fluid status, metabolic 
imbalance and the concurrent administration of other 
drugs in these patients cause a larger variation in the 
response to muscle relaxants. Therefore, abnormal 
reactions to all agents should be anticipated, and the 
variability in response is larger in patients with than in 
patients without renal diseases. Good clinical practice 
demands, especially in patients with renal failure, the 
administration of the smallest dose necessary to 
achieve adequate relaxation in the individual patient; 
if possible, in the presence of close monitoring of neu­
romuscular function throughout the case.
The initial volume of distribution (central compart­
ment) of relaxants is not different in patients with 
renal failure; however, the elimination half life is, with 
most relaxants, changed. The reason is a larger vol­
ume of distribution and a reduced plasma clearance. 
Due to decrease in clearance administration of incre­
mental doses or continuous infusion of relaxants will 
generally cause prolonged neuromuscular blockade.
The elimination of gallamine is most affected in 
renal failure because the drug is not metabolized, but 
is almost entirely dependent on renal excretion (>
Table 2.4 Elimination and metabolism of relaxants over 24 ƒ). Data randomly chosen from the literature
Drug Renal elimination Biliary excetion Metabolism
Suxamethonium 0 % 0 % 1 0 0 % plasma
Cholinesterase
Tubocurarine 45-60% 10-40% 0 %
Metocurarine 60-90% < 1 0 % 0 %
Doxacurium 25-50% ?» 50-70%
Atracurium 6 -1 0 % 0 % 90% Hofmann elim. 
Carboxylesterase
Cisatracurium
Mivacurium < 1 0 % 0 % 1 0 0 % plasma
Cholinesterase
Pancuronium 60-90% 20-30% 35% liver
Pipecuronium 50-60% 20-30% 2 0 % liver
Vecuronium 20-30% 50-60% 35% liver
Rocuronium 20-30% ■i* ^ liver
Alcuronium 80-90% 1 0 % 0 %
Gallamine 95-98% 2-5% 0 %
95%). Especially when larger or repeated doses are 
administered, an increase in the duration of action is 
observed [198]. The effect of tubocurarine, excreted 
for 25-60% via the kidneys, is known to be prolonged 
in renal failure. The elimination half-life is increased
[199]. The plasma clearance of vecuronium is mainly 
excreted in the bile and atracurium is dependent on 
Hoffmann elimination. In patients under isoflurane 
anesthesia, vecuronium has a longer duration of 
action. Here a decreased plasma clearance and a pro­
longed elimination half-life as compared to patients 
with norma! renal function has been demonstrated. 
In another study it was found that the duration of 
action of atracurium in anephric patients is reduced 
when compared to patients with normal renal func­
tion; with repeated administrations the authors were 
unable to demonstrate a prolongation in the effect. In 
the same study, a longer effect of pancuronium in 
anephrics and increase in duration after repeated 
administrations was observed. In the case of alcuroni­
um, metocurine and pancuronium the clearance is 
1.5-5 times diminished. Metocurine and alcuronium 
are excreted almost entirely (60-90%) unchanged by 
the kidneys; fazadinium is excreted largely unchanged 
by the kidneys (25-60%) and only to a minor extent is 
it metabolized by the liver. Mivacurium is metabolized 
by plasma cholinesterase; however, in a study on con­
tinuous infusion of mivacurium in anephric patients, a 
lower infusion rate was needed to maintain a certain 
degree of blockade, and recovery lasted longer when 
compared to patients with normal renal function
[200]. Recently a case was reported in which a single 
dose of mivacurium lasted extremely long in a patient 
with renal failure [ 2 0 1  ].
Vecuronium, atracurium and suxamethonium or 
their metabolites are excreted only to a minor extent 
by the kidneys (< 25%). Rocuronium is excreted for 
20-30% by the kidneys. In some renal patients the 
duration of action is prolonged, in others not [2 0 2 ]. 
Approximately 40% of pipecuronium is excreted 
unchanged via the kidneys; more is renally excreted 
after hepatic metabolism. The elimination half-life is 
prolonged in renal failure, but, the duration of effect 
is not prolonged [203]. Pharmacokinetic data on non­
depolarizing relaxants in patients with and without 
renal failure are given in Table 2.5.
After renal transplant, cyclosporine is frequently 
administered for immunosuppression. A case in which 
cyclosporine prolonged the effect of pancuronium 
has been reported. This is a confirmation of animal 
experiments done so far.
Besides the prolonged effect that most muscle 
relaxants exhibit in patients with renal failure, anti­
cholinesterases also have a longer duration of action. 
This makes the prospect of recurarization after their 
administration nearly impossible.
2.5.2. The effect of hepatic diseases 
Because the muscle relaxants are water-soluble com­
pounds, the liver plays only a minor role in the excre­
tion of these compounds (see Table 2.4). However, 
the liver is important in the metabolism of some of 
them, especially the steroidal relaxants. Because drug 
metabolism is, most of the time, only affected in the 
later stages of cirrhosis, this disease in general will 
nog influence the duration of neuromuscular block­
ade.
In cholestasis, however, the uptake of in the liver is 
decreased, which decreases plasma clearance and 
leads to a prolonged effect [204]. Hepatic elimination 
of relaxants depends on hepatic blood perfusion, 
hepatic drug extraction, and drug binding to proteins 
[205]. Changes in these factors will result in different 
pharmacokinetics and hence altered pharmacody­
namics.
Pseudocholinesterase is produced by the liver. In 
hepatic disease a decrease in pseudocholinesterase 
may thus lead to a prolonged effect of suxametho­
nium.
The liver is not involved in the elimination of atra­
curium and gallamine, is only of minimal importance 
in the elimination of atracurium and gallamine, and is 
only of minimal importance in the elimination of 
metocurine. Only about 10% of alcuronium, pancu­
ronium, vecuronium and tubocurarine, and even less 
metocurine and gallamine, is excreted in the bile. This 
amount may (except for gallamine) be increased 
when renal failure exists. The liver is more important
T ab le  2,5 Pharmacokinetic data of non-depolarizing relaxants in normal and renal failure patients. Data
randomly collected from the literature and rounded
Drug Vdss l/kg Clp (ml/kg/min) tVielim.min
Normal Renal Normal Renal Normal Renal
Tubocurarine 0.25 0.25 2.4 1.5 84 132
Metocurarine 0.15 0.24 1.3 0.38 360 684
Doxacurium 0 . 2 2 0.27 2 . 6 6 1.16 99 2 2
Atracurium 0,18 0 . 2 2 6 .1 6.7 21 24
Cisatracurium 0.15 0.15 4.18 3.62 30 34
Mivacurium 0 .1 1 0.15 70.3 76.5 18 34
Pancuronium 0.15 0,24 1 .0 0.3 1 0 0 489
Pipecuronium 0.31 0.44 2,3 1 . 6 6 137 263
Vecuronium 0 . 2 0 0.24 5.3 3.1 53 83
Rocuronium 0 .2 1 0 .2 1 3.7 2.5 97 104
Alcuronium — m — tar
Gallamine 0 .2 1 0,28 1 . 2 0.24 131 752
in the metabolism of pancuronium (25-40%) and 
vecuronium (20-35%), which after such metabolism 
are mainly excreted in the urine. Hepatic diseases, 
however, do Interfere with this metabolism and alter 
the pharmacodynamic profile of the drugs involved. 
Patients with chronic liver disease are resistant to a 
number of muscle relaxants, which also have a slower
onset of action. In cirrhotic patients this is the result of 
an increase in the volume of distribution, leading to a 
lower plasma concentration when the same dose is 
administered. This phenomenon can be observed 
with pancuronium, tubocurarine and atracurium, but 
not with gallamine. The larger volume of distribution of vecuronium [218]. 
will also result in an increased terminal half-life, and
under decreased linearly with the temperature [215]. 
There was a difference between patients with active 
or passive cooling. In a following study was it demon­
strated that the effect of local surface cooling on mus­
cle contraction was less than that of central core cool­
ing [216]. Maintaining central temperature is thus of 
primary importance. Cooling does not affect train-of- 
four ratio. In mild intraoperative hypothermia a signif­
icant increase in duration of action and a significantly 
decrease in recovery rate were observed for vecuro­
nium [217], Higher sensitivity during hypothermia 
has also been demonstrated for continuous infusion
thus prolong the duration of action. There is no resis­
tance to vecuronium in cirrhotic patients, but the 
duration of action is prolonged. In patients with alco- 
hol-related liver disease (cirrhosis), the pharmacoki­
netics and duration of action of vecuronium at a dose 
of 0 .1  mg/kg were not shown to be different from 
normal patients. However, an unexplainable slower 
onset of action was present Rocuronium has a higher 
initial volume of distribution in cirrhoses, which is 
reflected in a slower onset and longer duration and 
recovery in cirrhotic patients [206 207].
In cholestatic patients the decrease in plasma elimi­
nation results in a prolonged duration of action with 
tubocurarine, pancuronium and vecuronium and, to 
a small degree, also with gallamine. The increased 
plasma concentration of bile salts in these patients 
reduces the liver uptake of vecuronium and pancuro­
nium. in hepatitis, there is a decrease in plasma clear­
ance, resulting in a longer duration of action.
2.5.3. The effect of acid-base balance disturbances
Acid-base imbalance interferes with muscle relaxation 
through various mechanisms such as alteration in 
protein binding, changes in electrolyte distribution, 
and in acetylcholine releases etc. Decrease in pH (aci­
dosis) potentiates the monoquarternary relaxants 
(tubocurarine, vecuronium, rocuronium), but antago­
nizes the effects of the bisquarternary relaxants 
(metocurine, pancuronium) [208 209].
2.5.4. The effect of temperature changes
Hypothermia decreases the contraction force of the 
adductor pollicis muscle even without the presence of 
muscle relaxants when measured with mechanomyo- 
graphy, but an increase occurs when measured with 
electromyography [210]. Hypothermia during 
anaesthesia can occur spontaneously or may be 
induced as with cardiopulmonary bypass. In cardio­
pulmonary bypass it was demonstrated that cooling 
as such caused an increase in potency and a prolon­
gation in the duration of pancuronium and vecuro­
nium through an effect at the neuromuscular junction 
rather than through a change in pharmacokinetics 
[211], This is in agreement with the increased sensi­
tivity at the cat neuromuscular junction found in the 
past [212]. The effect of hypothermia is reversed 
upon rewarming. Similar data in cardiopulmonary 
bypass have been found with d-tubocurarine and 
alcuronium [213]. Also the atracurium effect is 
enhanced in hypothermia [214, 17]. Studies without 
the use of cardiopulmonary bypass demonstrated 
that the twitch contraction of the adductor pollicis 
muscle remains unchanged above 35.2° C and there-
2.5.5. The effect in neurological diseases
In many neural and neuromuscular diseases the 
administration of suxamethonium is accompanied by 
massive potassium release resulting in hyperkalaemia 
[56]. Such hyperkalemia has been seen in hemiplegia 
[219], paraplegia [2 2 0 ], in encephalitis [2 2 1 ], diffuse 
intracranial lesions [2 2 2 ], ruptured cerebral aneurysm 
[223], peripheral neuropathy [224], and in peripheral 
denervation [225]. The potassium release is most like­
ly due to extension of the muscular junctions (and 
acetylcholine receptors) beyond the original motor 
endplate and is called 'extrafunctional chemo- 
sensitivity'. It is seen in all muscle denervation lesions, 
starting as early as one week and as late as six months 
after the accident, and has an unknown duration.
Central motor neuron lesions (cerebral location, i.e. 
hemiplegia) have been associated with resistance to 
non-depolarizing muscle relaxants at the afflicted 
side, and with hyperkalemia following administration 
of suxamethonium [226-228, 56]. The changes occur 
already 2  days after the beginning of the hemiplegia. 
The reason is probably the sprouting of remaining 
axons with spread of the increased number of acetyl­
choline receptors (extrajunctional chemosensitivity). 
Also in patients with diffuse intracranial lesions, rup­
tured cerebral aneurysm, and closed head injury, 
increased potassium release upon suxamethonium 
administration and resistance to non-depolarizers has 
been observed [229]. This may lead to inadvertant 
mortality.
In lower motor neuron lesions (spinal cord loca­
tion, i.e. paraplegia, quadriplegia), however, increas­
ed response to non-depolarizers is observed at the 
afflicted side [230]. There is supersensitivity to suxam­
ethonium, which can also in this situation lead to 
hyperkalaemia [231 232]. The origin of the effects in 
lower motor neuron lesions is a sprouting of acetyl­
choline receptors [233]. It has even been reported 
after transient paraplegia [234]. Muscular contrac­
tures may occur spontaneously or following suxame­
thonium administration in denervated muscles [76]. 
In amyotrophic lateral sclerosis suxamethonium may 
induce a myotonia-like contracture [235],
One to two weeks following peripheral muscular 
denervation (peripheral nerve damage) extrajunc­
tional chemosensitivity and decrease in plasma choli- 
nesterase activity develops. Thus an increased 
response to suxamethonium will occur; even myoto­
nic contractures may be seen. There is a normal 
response to non-depolarizers in denervation disorders 
[236]. Reinnervation restores both the number of ace­
tylcholine and receptor and their function, whereas 
induced muscle activity restores their function. This
does normalize the sensitivity for suxamethonium.
In multiple sclerosis [237] contractures and rhab- 
domyolysis may occur after administration of suxa­
methonium.
In Myasthenia Gravis there is a functional decrease 
in the number of postsynaptic acetylcholine recep­
tors. There is resistance for succinylcholine, which also 
more rapidly leads to a slowly recovering phase II 
block. Most non-depolarizing muscle relaxants are 
more potent than in other patients and thus the dose 
must be reduced by 50-75%.
Lambert-Eaton Myasthenic Syndrome (LEMS) is an 
autoimmune disorder in which the acetylcholine 
release is decreased. The production of autoantibod­
ies seems to be initiated by tumor cells. In a group of 
patients with LEMS was it shown that the antibodies 
react with, amongst other presynaptic proteins, 
synaptotagmin which is involved in acetylcholine 
endocytosis [238]. The patients are very sensitive to 
the effect of muscle relaxants.
The various forms of the inheritant neuromuscular 
disorder myotonia (myotonic dystrophy, myotonia 
congenita and paramyotonia congenita) demonstrate 
an abnormal delay in relaxation after muscle contrac­
tion. When succinylcholine is administered to these 
patients, a sustained (myotonic) contraction will 
occur. The response to non-depolarizing muscle 
relaxants is generally normal, although many patients 
are more sensitive and demonstrate a prolonged 
effect. When anticholinesterases are administered 
myotonic responses may also be observed.
Patients with epilepsia are chronically treated with 
anticonvulsants. In the past a resistance toward non­
depolarizing relaxants, i.e. pancuronium, vecuronium 
and metocurine, has been described in patients 
receiving carbamazepine or phenytoine, Recently a 
case of resistance to pancuronium but not to atracuri­
um has been described in a patient receiving pheny- 
toin. However, a prospective study demonstrated 
resistance also to atracurium in patients chronically 
treated with phenytoin [239].
2.6.Drug interactions with non-depolariz­
ers
More than 250 drugs have an effect on the neuro­
muscular transmission and hence interfere pharma- 
codynamicaily with muscle relaxants [2], Some drugs 
such as local anaesthetics, inhalational and intrave­
nous anaesthetics, and antibiotics, cause blockade of 
the open ion channels [240]. Such an ion-channel 
block is non-stereospecific, whereas acetylcholine 
receptor block is stereospecific. Other drugs may 
interfere with the metabolism or excretion of the 
relaxants and thus pharmacokinetically interact.
2.6,1. Inhalation anaesthetics
Inhalational anaesthetics decrease the duration of 
miniature end-plate currents resulting in decrease in 
open time for the acetylcholine receptor [241 242]. 
This is likely the result of an increase in the acetylcho­
line binding affinity [243 244], Thus inhalation 
anaesthetics increase the potency of, and prolong the 
neuromuscular blockade from, most non-depolariz­
ing relaxants. Enflurane has the strongest effect, than 
isoflurane, followed by halothane. Also, the new 
inhalants sevoflurane and desflurane potentiate the
relaxants [245-247]. Such effects are dependent on 
the concentration and the duration of administration
[248]. The effect is more pronounced with the long- 
er-acting relaxants than with the shorter-acting ones. 
Also, inhalational anaesthetics diminish the interindi- 
vidual variability in the effect of muscle relaxants
[249].
2.6.2. Intravenous anaesthetics
Some intravenous anaesthetics also have this effect
[250]. Ketamine, meperidine, and propofol have po­
tentiating effects in clinical concentrations; fentanyl, 
alphaxalone, diazepam, and etomidate oniy at signifi­
cantly higher concentrations [251]. Methohexitone 
and etomidate have similar effects [252]. Similar 
effects of anaesthetics on brain acetylcholine recep­
tors may be involved in causing the state of general 
anaesthesia.
2.6.3. Antibiotics
The aminoglycoside, lincosamide, and polypeptide 
antibiotics are especially known to interfere with neu­
romuscular transmission and thus to interact with the 
effect of relaxants [253 254]. The main mechanism is 
decrease in acetylcholine release [255]. The poly­
peptides also have local anaesthetic effects on the 
nerve, and depress muscle action potential [256]. The 
antibiotics can cause curarization when administered 
up to 4-6 h after complete recovery of the neuromus­
cular blockade, even when antagonized with neostig­
mine or pyridostigmine (Booij, unpublished data). 
The polymyxins have a local anaesthetic effect in that 
they block the acetylcholine receptor ion-channel, 
which is not reversed by anticholinesterases and only 
partly by 4-aminopyridine [257]. Aminoglycosides 
decrease acetylcholine release and they lower the 
postjunctional sensitivity for acetylcholine [258]. 
Again, neostigmine has little reversing effect on such 
a blockade. Tetracyclines interfere with calcium, 
which is involved in acetylcholine release [259]. 
Neostigmine has no effect. Lincomycin and clindamy­
cin block ion channels and depress muscle contractil­
ity [260]. Both neostigmine and 4-aminopyridine are 
partially effective in antagonizing the blockade [261]. 
It should be remembered that in patients with myas­
thenia gravis muscle paralysis can develop when ami­
noglycoside, lincosamide or polypeptide type of anti­
biotics are administered without concomitant admin­
istration of relaxants. This is also the case when pro­
cainamide, quinine or quinidine are given for the 
treatment of cardiac arrhythmias [262].
2.6.4. Interaction between relaxants
Pancuronium and pipecuronium markedly inhibit 
plasma cholinesterase, and thereby prolong the effect 
of suxamethonium [263]. The combination of dissimi­
lar relaxants appear to potentiate each other's effects
[264]. The administration of combinations of particu­
lar relaxants, e.g. pancuronium and metocurine, gal­
lamine and metocurine, and tubocurarine and pancu­
ronium, can lead to a faster onset of action, but can 
also lead to a potentiation or prolongation of effect
[265]. Combination of relaxants with similar structure 
causes additive effects [266].
2.6.5. Miscellaneous drugs
In has been demonstrated that the duration of action
of vecuronium is prolonged in parturients treated 
with cimetidine [267]. Ranitidine does not have this 
effect [268].
In one study was it demonstrated that smokers are 
more sensitive to atracurium because of receptor 
down regulation [269]. In another study was it found 
that they are resistant to vecuronium [270].
Local anaesthetics, quinidine and calcium channel 
blockers interfere with neuromuscular transmission 
via blockade of open acetylcholine receptor operated 
ion-channels [271]. The blockade from calcium chan­
nel blockers (nifedipine, diltiazem) remains reversible 
by anticholinesterases [272].
Phosphodiesterase inhibitors (aminophylline, theo­
phylline) potentiate the effect of suxamethonium and 
antagonize the non-depolarizing relaxants [273]. The 
mechanism is likely to be an increase in acetylcholine 
release from a phosphodiesterase inhibition leading 
to increased prejunctional cyclic AMP.
Magnesium sulphate, frequently used in (pre-) 
ecclampsia, does prolong the effect of the non-depo­
larizers in a dose-related manner. It inhibits the effect 
of suxamethonium [274].
Cyclosporine, used to prevent rejection after organ 
transplantation, has been reported to prolong the 
effect of pancuronium [275].
Patients with epilepsia are chronically treated with 
anticonvulsants. In the past a resistance toward non­
depolarizing relaxants, i.e. pancuronium, vecuronium 
and metocurine, has been described in patients 
receiving carbamazepine or phenytoine [276]. There 
seems to be no effect on atracurium. In a prospective 
study, however, resistance to atracurium in 23 
patients chronically treated with phenytoin was also 
found. Steroids can cause resistance to non-depolariz­
ers [277 278]. This has recently been confirmed for 
betamethasone in both animals and patients [279 
280]. It is likely to be the result of increased prejunc­
tional acetylcholine release.
2.7.Side~effects of non-depolarizers
The presently clinical available muscle relaxants all 
have side-effects. Muscle relaxants seem to be 
responsible for 50% of the adverse reactions during 
anaesthesia [281]. Residual curarization can contri­
bute to postoperative respiratory depression [282].
2.7.1. Cardiovascular effects
Many compounds of both the benzylisoquinoline and 
steroidal group have cardiovascular effects through a 
number of mechanisms [283]. Some of the effects are 
mediated by an effect of the relaxants on muscarinic 
acetylcholine receptors in the parasympathic nervous 
system, or through ganglionic nicotinic acetylcholine 
receptors in the sympathetic system (see Table 2.6) 
[284]. For example, pancuronium and alcuronium 
block cardiac muscarinic receptors (M2) at doses used 
for neuromuscular blockade. Tubocurarine, metocu­
rine, atracurium, and vecuronium do so at doses far 
greater than necessary for neuromuscular blockade. 
Thus the bradycardic effects of other drugs, i.e. nar­
cotics, will be seen at induction of anaesthesia [285- 
288]. Pipecuronium and doxacurium have little vago­
lytic effect at high doses (3-4 x ED95). Pancuronium 
causes tachycardia and hypertension by noradrena­
line reuptake block. Sympathetic effects of pancuro­
nium may also influence pulmonary circulation and 
result in pulmonary vasoconstriction and thus in ven­
tilation/perfusion mismatch. This has been noted dur­
ing intensive care in neonates [289].
Atracurium and tubocurarine also exert cardiovas­
cular responses through histamine release. 
Laudanosine exhibits a strong noradrenaline releasing 
action, which may contribute to the tachycardia 
shown after administration of atracurium [290]. 
Tubocurarine causes marked ganglion blockade, 
resulting in hypotension, in doses similar to those 
producing neuromuscular block. Also, it has a direct 
myocardial depressant effect. Rocuronium in higher 
doses, due to a slight vagolytic effect, causes occa­
sional tachycardia and hypertension [291 292].
In one study, the use of non-depolarizing muscle 
relaxants increased the risk of a cardiopulmonary 
complication postoperatively [293].
In conclusion: Tubocurarine and pancuronium 
cause the most marked cardiovascular effects of all 
currently used non-depolarizing relaxants, the effects 
of atracurium and mivacurium are fewer and are 
more related to histamine release. Rocuronium has 
slight vagolysis, whereas doxacurium, pipecuronium, 
and vecuronium are virtually free from cardiovascular 
effects.
In a study of 433 patients, it was demonstrated 
that 30% (133) of the patients admitted to a PACU 
experienced one or more complications, with 58% 
(77) of those having had a muscle relaxant [294]. In 
23 patients, a tachyarrhythmia developed; 20 of 
these patients had received a relaxant. Of the 13 
patients who developed postoperative hypertension, 
11 had received a relaxant. Of the 33 patients who 
developed hypotension, 1 2  had received a relaxant. 
Muscle relaxants may thus contribute to postopera­
tive morbidity.
2.7.2. Histamine release
The benzylisoquinoline type muscle relaxants are 
potential histamine releasers. This release is related to 
the dose and the speed of administration [295]. 
Intradermal injection of relaxants in humans causes 
the production of wheals and flares [296 297], 
Tubocurarine and, to a lesser degree, atracurium are 
the strongest histamine releasers, followed by meto­
curine and mivacurium. Suxamethonium and galla­
mine have about half the histamine releasing potency 
of tubocurarine [298]. Histamine release after doxa- 
curium and cisatracurium is minimal. The steroidal 
relaxants are all free from histamine-releasing proper­
ties (see Table 2.6) [299]. The symptoms of histamine 
release correlate with its plasma level: between 3 and 
1 0  mg/ml causes flushing, urticaria and tachycardia, 
between 1 0  and 1 0 0  ng/ml severe bronchospasm 
and hypotension, and concentrations above 1 0 0  
ng/ml causes cardiovascular collapse [300].
Apart from histamine release problems can occur 
from allergic/anaphylactic reactions. Suxamethonium 
(38 per million patients) and alcuronium (33 per mil­
lion) are the two relaxants most involved in anaphy­
lactoid reactions, followed by gallamine (30 per mil­
lion), then tubocurarine (29 per million) [301]. 
Atracurium (14 per million) and vecuronium (13 per 
million) have an about equally lower incidence, 
whereas pancuronium is lowest (9 per million). There 
exist cross-sensitivity on intradermal testing between
Table 2.6 Autonomic nervous system effects and histamine release
Relaxant Autonomic
ganglia
Cardiac
muscarine
receptors
Histamine
release
NMB- 
Vagai Ratio
Alcuronium weak none slight 5
Atracurium none none moderate 25
Cisatracurium none none none 27
Doxacurium none none slight 300
Gallamine none strong block non 0.5
Metocurine weak block none slight 17
Mivacurium none none mild 1 0 0
Pancuronium none weak block none 3
Pipecuronium none none none 25
Rocuronium none none none 5
Tubocurarine block none strong 1.5
Vecuronium none none none 50
prior nondepolarising blockade. Anesthesiology 1986;65:
the various relaxants, and thus it is difficult to attrib­
ute the reactions to specific antibodies. This is sup­
ported by the fact that reactions can occur to first 
exposure to the drug, and thus sensibilization could 
not have taken place. It has been suggested that the 
quaternary aminogroups play a role; these are 
present in many other compounds such as cosmetics, 
drugs, household agents and food,
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